Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) ...
How might the Q2 results influence valuation multiples (e.g., EV/EBITDA, price‑to‑sales) for SLN compared to its peers?
Are there any upcoming catalysts (e.g., conference presentations, data releases) that could drive the stock price in the near term?
What regulatory hurdles or FDA/EMA milestones could affect the timeline to approval for divesiran?
21 days ago